To fulfill all these criteria and to efficiently screen for compounds capable of reversing GAA-induced transcriptional silencing of FXN, we generated a novel reporter line using cells derived from a patient with FRDA, thus enabling the investigation of endogenous FXN levels impacted by long GAA repeats. The gene discussed is FXN; the disease is Friedreich ataxia.